Browsing by Author "Tusquets Trias de Bes, Ignacio"

Sort by: Order: Results:

  • Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study
    Peremiquel-Trillas, Paula; Tusquets Trias de Bes, Ignacio; Castaño Vinyals, Gemma; Kogevinas, Manolis; Costas, Laura (Elsevier, 2019)
    BACKGROUND: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the ...
  • Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study
    Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Rial, Abora; Cos, Maria Lourdes; Campodarve, Isabel; Rodriguez-Morera, Jaime; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Springer, 2019)
    PURPOSE: The most frequent adverse effects of aromatase inhibitors (AI) are arthralgia and bone loss induction. These reduce the quality of life of patients and their adherence to the treatment. This study evaluates the ...
  • Bone health evaluation one year after aromatase inhibitors completion
    Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Casamayor, Guillem; Cos, Maria Lourdes; Rial, Abora; Rodriguez-Morera, Jaime; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Elsevier, 2018)
    Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The ...
  • Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
    Tamborero Noguera, David; Rubio Pérez, Carlota, 1990-; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets Trias de Bes, Ignacio; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Torres, Carmen de; Dienstmann, Rodrigo; González-Pérez, Abel; López Bigas, Núria (BioMed Central, 2018)
    While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a ...
  • Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
    Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
    Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Evolución de la DMO durante el tratamiento con inhibidores de aromatasa y su relación con el gen CYP11A1: estudio prospectivo de la cohorte B-ABLE
    Rodríguez Sanz, Maria, 1984-; Prieto-Alhambra, Daniel; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Garrigós, Laia; Albanell Mestres, Joan; Martinez-García, Maria; González, I.; Martos, Tamara; Díez Pérez, Adolfo; Tusquets Trias de Bes, Ignacio; Nogués Solan, Francesc Xavier (Sociedad Española de Investigación Ósea y del Metabolismo Mineral, 2015)
    Objetivos: El objetivo del estudio fue analizar los cambios en la densidad mineral ósea (DMO) a lo largo del tratamiento con inhibidores de aromatasa (IA) en la práctica clínica y evaluar la asociación entre el gen CYP11A1 ...
  • FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors.
    Carracedo, Alma; Egervari, Kristof; Salido, Marta; Rojo, Federico; Arumí, Montserrat; Corominas Torres, Josep Maria; Corzo, Cristina; Tusquets Trias de Bes, Ignacio; Espinet Solà, Blanca; Rovira Guerín, Ana; Albanell Mestres, Joan; Szollosi, Zoltan; Serrano Figueras, Sergi; Solé Ristol, Francesc (BioMed Central, 2009)
  • Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates
    Pineda-Moncusí, Marta; Garcia Giralt, Natàlia; Díez Pérez, Adolfo; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Prieto-Alhambra, Daniel; Nogués Solan, Francesc Xavier (Wiley, 2020)
    Aromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteoporotic fractures. Currently, bisphosphonates are recommended to reduce fracture risk in these patients. The aim of this ...
  • Interplay between Natural killer cells and Anti-HER2 antibodies: Perspectives for breast cancer immunotherapy
    Muntasell i Castellví, Aura, 1972-; Cabo, Mariona, 1991-; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; López-Botet, Miguel (Frontiers, 2017)
    Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy ...
  • Perinatal and childhood factors and risk of breast cancer subtypes in adulthood.
    Lope, Virginia; Gracia Lavedan, Esther; Pumarega Rodríguez, José Antonio; Tusquets Trias de Bes, Ignacio; Kogevinas, Manolis; Castaño Vinyals, Gemma; Pollan, Marina (Elsevier, 2016)
    BACKGROUND: Accumulated exposure to hormones and growth factors during early life may influence the future risk of breast cancer (BC). This study examines the influence of childhood-related, socio-demographic and anthropometric ...
  • Potential clinical relevant drug-drug interactions: comparison between different compendia, do we have a validated method?
    Conde Estévez, David; Echeverría Esnal, David; Tusquets Trias de Bes, Ignacio; Albanell Mestres, Joan (Oxford University Press, 2015)
  • TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
    Rodríguez Sanz, Maria, 1984-; Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Martos, Tamara; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rodriguez-Morera, Jaime; Díez Pérez, Adolfo; Albanell Mestres, Joan; Nogués Solan, Francesc Xavier (Elsevier, 2016)
    INTRODUCTION: Patients with breast cancer under aromatase inhibitor (AI) treatment often develop osteoporosis and their average bone loss rate is twice that of natural reduction during menopause, increasing fracture risk. ...
  • The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study.
    Gómez-Acebo, Inés; Tusquets Trias de Bes, Ignacio; Castaño Vinyals, Gemma; Kogevinas, Manolis; Llorca, Javier (Public Library of Science (PLoS) , 2016)
    INTRODUCTION: The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled ...
  • Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
    Pineda-Moncusí, Marta; Garcia Giralt, Natàlia; Díez Pérez, Adolfo; Tusquets Trias de Bes, Ignacio; Servitja Tormo, Sonia; Albanell Mestres, Joan; Prieto-Alhambra, Daniel; Nogués Solan, Francesc Xavier (SAGE Publications, 2020)
    Background: Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events, respectively, in addition to other side effects. This study analysed ...
  • Total effective xenoestrogen burden in serum samples and risk for breast cancer in a population-based multicase-control study in Spain.
    Pastor-Barriuso, Roberto; Fernandez, Mariana F.; Castaño Vinyals, Gemma; Whelan, Denis ; Pérez-Gómez, Beatriz; Llorca, Javier; Villanueva Belmonte, Cristina; Guevara, Marcela; Molina-Molina, Jose Manuel; Artacho-Cordón, Francisco; Barriuso-Lapresa, Laura; Tusquets Trias de Bes, Ignacio; Dierssen Sotos, Trinidad; Aragonés, Núria; Olea, Nicolás; Kogevinas, Manolis; Pollan, Marina (National Institute of Environmental Health Sciences, 2016)
    BACKGROUND: Most studies on endocrine-disrupting chemicals and breast cancer have focused on single compounds and have produced inconclusive findings. OBJECTIVES: We assessed the combined estrogenic effects of mixtures of ...
  • Vitamin D levels in mediterranean breast cancer patients compared with those in healthy women
    Pineda-Moncusí, Marta; García-Pérez, Miguel Angel; Rial, Abora; Casamayor, Guillem; Cos, Maria Lourdes; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Cano, Antonio; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Elsevier, 2018)
    To evaluate the vitamin D status of postmenopausal women with early estrogen-receptor-positive breast cancer and to compare it with that of healthy postmenopausal women from the same Mediterranean region. STUDY DESIGN AND ...